Annalisa T.
- Country
- Italy
- Department
- Oncology for pediatrics
Research Overview
- Phase 1b Open-Label Study of Epcoritamab in Pediatric Patients with Relapsed/Refractory Aggressive Mature B-cell Neoplasms
- Evaluation of Dexamethasone Versus Prednisone in Induction Therapy for Pediatric and Adolescent Lymphoblastic Lymphoma: A Randomized Controlled Trial
- Phase 3 Study of Busulfan, Melphalan, and Chemoimmunotherapy in High-Risk Neuroblastoma Patients with Insufficient Metastatic Response
Data & Insights
Has run more than one trial at 99 of 256 partner sites.
Specializations
Pediatric Oncology
Specialized in treating high-risk neuroblastoma in pediatric patients, exploring innovative therapeutic strategies including induction regimens, high-dose chemotherapy, and targeted radiotherapy approaches.
- Advanced Neuroblastoma Treatment
- Chemoimmunotherapy Integration
- Multi-phase Treatment Protocols
Focuses on developing comprehensive treatment strategies incorporating both conventional and novel therapeutic modalities.
Hematologic Malignancies
Investigates novel treatments for aggressive B-cell neoplasms in pediatric patients, with particular emphasis on targeted immunotherapy approaches for relapsed and refractory cases.
- B-cell Lymphoma Management
- Epcoritamab Applications
- CD20-Positive Malignancies
Specializes in developing treatment options for patients who have not responded to conventional therapies.
Lymphoma Research
Focuses on innovative immunotherapy combinations for classical Hodgkin lymphoma and non-Hodgkin lymphoma in pediatric and young adult populations.
- Immunotherapy Combinations
- Relapsed/Refractory Disease
- Age-Specific Treatment Protocols
Explores novel therapeutic approaches using relatlimab and nivolumab combinations across different age groups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.